NRP-1 expression is strongly associated with the progression of pituitary adenomas
NRP-1 expression is strongly associated with the progression of pituitary adenomas
复制标题
DOI：
10.3892/or.2014.3392
复制
发表时间：
2014-10-01
期刊：
影响因子：
4.2
通讯作者：
Yang, Seung-Ho
中科院分区：
文献类型：
--
作者：
Lee, Sang Won;Lee, Jung Eun;Yang, Seung-Ho
本研究的目的是确定与肿瘤进展或复发相关的预测标志物。我们研究了p53，Ki-67，Bax，Bcl-2，血管内皮生长因子（VEGF）-A，VEGFR-1，VEGFR-2和神经纤毛蛋白-1（NRP-1）在垂体腺瘤（PA）中的表达。我们比较了这些分子在原发和复发标本中的表达，以确定与肿瘤进展相关的预测标志物。19例患者在超过5年的随访中没有进展。9例患者在首次经蝶手术（TSS）后5年内发生肿瘤进展，并接受了再次TSS治疗腺瘤进展。与无进展组相比，进展组的肿瘤更大，海绵窦受累更常见。观察到NRP-1表达与肿瘤进展之间存在强相关性。Ki-67、p53、Bax、Bcl-2、VEGFR-1、VEGFR-2或VEGF-A表达与肿瘤进展无显著相关性。9例患者中有4例在进展标本中显示出强NRP-1免疫反应性。NRP-1免疫反应性在初始标本中的阴性在5例患者的进展标本中转化为强阳性。NRP-1可能是PA进展的相关标志物，并可能成为药物治疗的潜在靶点。
The purpose of the present study was to identify a predictive marker associated with tumor progression or recurrence. We investigated the expression of p53, Ki-67, Bax, Bcl2, vascular endothelial growth factor (VEGF)-A, VEGFR-1, VEGFR-2 and neuropilin-1 (NRP-1) in pituitary adenomas (PAs) with/without tumor progression during follow-up periods. We compared the expression of these molecules in primary and recurrent specimens to identify a predictive marker associated with tumor progression. Nineteen patients had no progression for more than 5-years of follow-up. Nine patients had tumor progression within 5 years of their first transsphenoidal surgery (TSS) surgery and underwent re-TSS for treating progression of adenoma. Tumor size was larger and involvement of the cavernous sinus was more frequent in the progression group than these variables in the no progression group. A strong association was observed between NRP-1 expression and tumor progression. No significant risk for developing tumor progression was associated with Ki-67, p53, Bax, Bcl-2, VEGFR-1, VEGFR-2, or VEGF-A expression. Four of nine patients showed strong NRP-1 immunoreactivity in progression specimens. Negative NRP-1 immunoreactivity in the initial specimens was converted into strong positivity in the progression specimens of five patients. NRP-1 could be a relevant PA marker of progression and could be a potential target for medical therapy.